In Brief: DynaGen
This article was originally published in The Gray Sheet
Executive Summary
DynaGen: Licenses breast biopsy technology from privately held BioLoc, Inc. that is intended to "overcome the shortcomings of the core needle biopsy procedure by accurately guiding the surgical biopsy instruments directly to the suspected tissue lesion identified during mammography examination." The technology will "allow us to enter the $1 bil. breast biopsy market with a differentiated product that will be an improvement over current procedures," DynaGen says, and will provide opportunities for "future innovative product offerings in cancer screening and diagnosis"...